The vaccine will target triple-negative breast cancer. If approved by the FDA, the vaccine will enter its second stage of the trial this year.

Mural nominated two new development candidates, MURA-8518 a novel binding protein-resistant IL-18 with half-life extension, ...

Researchers developed and validated a nomogram to predict 1-, 2-, and 3-year overall survival (OS) in patients with ovarian ...

CAMBRIDGE, Mass., Jan. 09, 2025 (GLOBE NEWSWIRE) -- Eterna Therapeutics (Nasdaq: ERNA), a leader in cell therapies for the treatment of advanced solid tumors, today announced the appointment of Elena ...

Findings from a multi-institutional, international study have significantly advanced the understanding of genetic alterations in the BRCA2 gene, a key player in hereditary cancer risk.

A new University of Cincinnati Cancer Center study has identified a particular strand of microRNA as a promising new target for overcoming breast cancer treatment resistance and improving outcomes.

Nuvectis Pharma’s NXP800 shows potential in ovarian cancer but is early stage. Find out why NVCT stock is best suited for ...

The US Food and Drug Administration (FDA) has accepted for priority review the new drug application (NDA) for avutometinib to be used in combination with defactinib for the treatment of adults with ...

An NDA has been accepted by the FDA for the combination of avutometinib and defactinib in KRAS-mutated recurrent low-grade ...

The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) under Priority Review for avutometinib, in combination with defactinib, for the treatment of adults with ...

Experts say ovarian cancer causes more deaths than all other female reproduction system cancers and is difficult to diagnose ...